Business
Rockwell Medical, Inc. Reports Third Quarter 2019 Financial Results
– Company reports first full quarter of results for Dialysate Triferic, highlighted by greater than 75% conversion rate from Triferic Evaluation Program – –
About this update from Rockwell Medical, Inc.
[{"type":"text","content":"– Company reports first full quarter of results for Dialysate Triferic, highlighted by greater than 75% conversion rate from Triferic Evaluation Program – – Signs leading East Coast academic medical center as first Center of Excellence –\n WIXOM, Mich., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD), today reported business highlights and financial results for the three- and nine-months ended September 30, 2019. “Our mission is to transform anemia management in a wide variety of disease states across the globe while improving patients’ lives. We believe Triferic is one of the most innovative advancements in patient iron management over the last two decades. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of dialysis, which we believe will enable Triferic to become, over time, the standard of care for ESRD patients. We are pleased with the early progress we are making with the commercialization of our Triferic portfolio,” stated Stuart Paul, President and Chief Executive Officer of Rockwell Medical. Recent Business and Financial Highlights: Key highlights for the Dialysate Triferic U.S. market introduction include:○ 1,000+ patients on therapy at 13 contracted clinics as of September 30, 2019;○ 1,300+ patients on therapy at 15 clinics enrolled in the Evaluation Program;○ Since launch, experienced 75% conversion rate of clinics in Evaluation Program; and○ The Company entered into its first contract with a Center of Excellence1 (“COE”) for the purchase of Dialysate Triferic.Appointed industry veteran John P. McLaughlin as Chairman of the Board of Directors, bringing over 30 years of executive and board experience in the biopharmaceutical industry;Continued to engage with the U.S. Food and Drug Administration (“FDA”) on review activities regarding the I.V. Triferic New Drug Application (“NDA”), with a PDUFA date of March 28, 2020;Committed to enhancing the Company’s medical capabilities to build a leading medical platform in the field of dialysis;Sales were $15.4 million and $45.8 million for the three and nine months ended September 30, 2019, respectively, including s...